Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 53s
Watch time: 4m 57s
Watch time: 8m 2s
Watch time: 3m 25s
Watch time: 4m 43s
Watch time: 4m 14s
Watch time: 7m 48s
Watch time: 7m 44s
Watch time: 10m 34s
Watch time: 9m 40s
Articles
Relationship Between VEGF-C Levels and Mortality in Patients with Peripheral Artery Disease
Citation:
European Cardiology Review 2018;13(2):123.
- Views:
40
- Downloads:
0
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors
Citation:
European Cardiology Review 2018;13(1):9–13.
- Views:
311
- Downloads:
0
Cardiovascular Implications of Sphingomyelin Presence in Biological Membranes
Citation:
European Cardiology Review 2018;13(1):42–5.
- Views:
163
- Downloads:
0
Guest Editorial: Reducing Risk in Familial Hypercholesterolaemia and Severe Dyslipidaemia: Novel Drugs Targeting PCSK9
Citation:
European Cardiology Review 2018;13(1):7–8.
- Views:
137
- Downloads:
0